

Table 13.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1997 to 2006
Recipients with Heart-Lung Transplants

	Year of Transplant									
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Transplants	62	47	51	48	27	33	29	40	35	31
Tx with Antirejection Treatments	13	25	18	16	4	8	8	12	10	13
Antibodies										
Any in Category	15.4%	20.0%	5.6%	18.8%	0.0%	0.0%	12.5%	16.7%	0.0%	38.5%
Atgam/NRATG/NRATS	7.7%	16.0%	0.0%	6.3%	0.0%	0.0%	12.5%	0.0%	0.0%	15.4%
OKT3	7.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Thymoglobulin	0.0%	4.0%	5.6%	0.0%	0.0%	0.0%	0.0%	16.7%	0.0%	15.4%
Zenapax	0.0%	0.0%	0.0%	12.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	7.7%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	7.7%
Corticosteroids										
Any in Category	100.0%	92.0%	94.4%	93.8%	100.0%	100.0%	62.5%	100.0%	100.0%	100.0%
Steroids	100.0%	92.0%	94.4%	93.8%	100.0%	100.0%	62.5%	100.0%	100.0%	100.0%
Antimetabolites										
Any in Category	0.0%	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Methotrexate	0.0%	4.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.